The use of positron emission tomography (pet) in the diagnosis of neurodegenerative diseases of the elderly

  • Cristina Maria Moriguchi Jeckel




Download data is not yet available.


Sokoloff L, Reivich M, Kennedy C, et al. The (14 C)-

deoxyglucose method for measurement of local cerebral

glucose utilization: theory, procedure and normal values in

the conscious and anesthetized albino rat. J Neurochem.


Pawlik G, Heiss WD. Positron emission tomography and

neuropsychological function. In: Bigler ED, Yeo RA,

Turkheimer E (eds). Neuropsychological function and brain

imaging. New York: Plenum Publ. Corp.; 1989. p. 65-138.

Heiss WD, Zimmermann-Meinzingen S. PET imaging in

the differential diagnosis of vascular dementia. J Neurol Sci.


Mosconi L. Glucose metabolism in normal aging and

Alzheimer’s disease: Methodological and physiological

considerations for PET studies. Clin Transl Imaging.


Salmon E. Functional brain imaging applications to

differential diagnosis in the dementias. Curr Opin Neurol.


Mosconi L, et al. FDG-PET changes in brain glucose

metabolism from normal cognition to pathologically

verified Alzheimer’s disease. Eur J Nucl Med Mol Imaging.


Herholz K, et al. Discrimination between Alzheimer

Dementia and Controls by Automated Analysis of

Multicenter FDG PET. Neuroimage. 2002;17(1):302-16.

Silverman DH, Small GW, Chang CY, et al. Positron emission

tomography in evaluation of dementia: Regional brain

metabolism and long-term outcome. JAMA. 2001;286(17):


De Santi S, de Leon MJ, Rusinek H, et al. Hippocampal

formation glucose metabolism and volume losses in MCI

and AD. Neurobiology of aging. 2001;22(4):529-39.

Gauthier S, et al. Mild cognitive impairment. Lancet.


Jeong Y, et al. 18F-FDG PET Findings in Frontotemporal

Dementia: An SPM Analysis of 29 Patients. J Nucl Med.


Foster NL, et al. FDG-PET improves accuracy in

distinguishing frontotemporal dementia and Alzheimer’s

disease. Brain. 2007;130:2616-35.

Spehl TS, Hellwig S, Amtage F, et al. Syndrome-Specific

Patterns of Regional Cerebral Glucose Metabolism in

Posterior Cortical Atrophy in Comparison to Dementia

with Lewy Bodies and Alzheimer’s Disease-A [F-18]-Fdg

Pet Study. J Neuroimaging. 2015;25(2):281-8.

Bohnen NI, Koeppe RA, Minoshima S, et al. Cerebral

glucose metabolic features of Parkinson disease and

incident dementia: longitudinal study. J Nucl Med. 2011;


Diehl-Schmid J, Grimmer T, Drzezga A, et al. Decline of

cerebral glucose metabolism in frontotemporal dementia:

a longitudinal 18F-FDG-PET-study. Neurobiol aging.


Mosconi L, et al. Multicenter standardized 18F-FDG

PET diagnosis of mild cognitive impairment, Alzheimer’s

Disease, and other dementias. J Nucl Med. 2008;49(3):


Gomperts SN, Rentz DM, Moran E, et al. Imaging

amyloid deposition in Lewy body diseases. Neurology.


Antonini A, et al. Differential diagnosis of parkinsonism

with FDG and PET. Mov Disord. 1998;13:268-74.

Eckert T, et al. FDG PET in the differential diagnosis of

parkinsonian disorders. Neuroimage. 2005;26:912-21.

How to Cite
Jeckel, C. M. M. (2017). The use of positron emission tomography (pet) in the diagnosis of neurodegenerative diseases of the elderly. PAJAR - Pan American Journal of Aging Research, 5(1), 4-6.